MetaCure Implant For Type 2 Diabetes: Overseas Trials To Wrap Up By 2012
This article was originally published in The Gray Sheet
Executive SummaryMetaCure plans to wrap up three overseas trials by the end of 2012 for its DIAMOND electrostimulator implant for type 2 diabetes in obese patients and will begin a pivotal U.S. trial within the next couple of years to support a PMA submission for type 2 diabetes.
You may also be interested in...
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.